New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma
Study
Phase 3, open label, randomized study (RELEVANCE)
|
Untreated grade 1-3a FL
|
R2 (n:513) or R-chemo (n:517), followed by rituximab maintenance
|
Efficacy
ORR: 61% and 65%, CR/CRu: 48% and 53% (p: 0.10)
|
PFS did not differ HR= 1.03 [95% CI, 0.84 to 1.27], P = .78)
|
6 year PFS: 60% (95% CI, 55 to 64) and 59% (95% CI, 54 to 64)
|
6 year OS: 89% in both groups
|
Safety
≥ grade 5 TEAE: 9 patients and 6 patients
|
Second primary malignancies 57 (11%) patients and 67 (13%) patients
|
Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022
